TRCT
CAMP icon

Tower Research Capital (TRC)’s CAMP4 Therapeutics CAMP Stock Holding History

Tower Research Capital (TRC)’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.19K Buy
1,873
+468
+33% +$2.02K ﹤0.01% 4087
2026
Q1 		$6.2K Buy
1,405
+999
+246% +$4.74K ﹤0.01% 4073
2025
Q4 		$2.49K Sell
406
-5,243
-93% -$22.3K ﹤0.01% 4512
2025
Q3 		$16.9K Buy
5,649
+1,819
+47% +$3.37K ﹤0.01% 3454
2025
Q2 		$5.55K Buy
+3,830
New +$7.62K ﹤0.01% 4174
2025
Q1 		– Sell
-3,680
Closed -$19.2K – 5245
2024
Q4 		$19.2K Buy
+3,680
New +$30.2K ﹤0.01% 3218

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tower Research Capital (TRC)'s CAMP Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its CAMP4 Therapeutics (CAMP) stake by 33% in Q2 2026, buying an estimated $2.02K and bringing the position to 1,873 shares worth $8.19K. The position accounts for ﹤0.01% of the portfolio, ranked #4087.

Tower Research Capital (TRC) first reported a position in CAMP in Q4 2024 and has held it in 6 quarters since. The position peaked at $19.2K in Q4 2024. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Tower Research Capital (TRC) held 1,873 shares of CAMP4 Therapeutics worth $8.19K as of Q2 2026.
  • Tower Research Capital (TRC) bought 468 CAMP4 Therapeutics shares in Q2 2026, an estimated $2.02K.
  • CAMP4 Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4087 holding.
  • Tower Research Capital (TRC) first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Tower Research Capital (TRC)'s CAMP4 Therapeutics position peaked at $19.2K in Q4 2024.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.